0329 GMT - Dai-ichi Life's purchase of a 15% stake in Challenger seems to support Citi analyst Nigel Pittaway's argument that the Australian wealth manager looked inexpensive. Pittaway, who already had a buy rating on the stock, tells clients in a note that the Japanese company's entrance on Challenger's share registry should support a higher valuation even if no full takeover is in the pipeline. He sees the timing of the transaction as interesting given the sell-off in global equities but reckons that it indicates a long-term positive view of Australia's retirement market. Citi has a A$6.70 target price on the stock, which is up 6.3% at A$5.89. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
April 06, 2025 23:29 ET (03:29 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.